Mass Medical Angels

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Coviu is a telehealth startup focused on enhancing the video consultation experience between healthcare practitioners and patients through AI-backed clinical tools. The company provides a platform that facilitates online health consultations across various specialties, including cardiology, dermatology, psychology, and pediatrics, among others. Coviu's software offers an integrated marketplace of clinical tools, which can be utilized during video consultations to improve patient care. Additionally, the platform seamlessly integrates with various practice management systems, allowing healthcare providers to access validated clinical resources and support from any consumer device. This comprehensive approach aims to make telehealth consultations as effective as in-person visits.

Capillary Biomedical, Inc. is a medical device company founded in 2014 and located in Irvine, California. The company focuses on developing innovative technologies for diabetes management, particularly in simplifying glucose monitoring and insulin delivery. As a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University, Capillary Biomedical is dedicated to reducing the burden of diabetes on patients and the healthcare system. Its flagship product features a kink-proof, flexible, multiport cannula designed for reliable and comfortable insulin delivery, with an emphasis on a straightforward one-handed insertion process. This user-friendly design aims to assist diabetes patients in achieving better blood glucose control.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Sentien Biotechnologies, Inc. is a clinical-stage company focused on developing innovative cell therapies aimed at restoring immune system balance and enhancing treatment options for patients with systemic inflammatory diseases. Founded in 2008, the company is headquartered in Medford, Massachusetts. Its flagship product, SBI-101, utilizes a novel blood conditioning approach that immobilizes Mesenchymal Stromal Cells (MSCs) in an extracorporeal device, allowing for sustained and controlled release of anti-inflammatory and regenerative molecules. This method significantly enhances the therapeutic activity of MSCs compared to traditional delivery methods like direct injection or intravenous infusion. Sentien Biotechnologies also offers the Sentinel device, which supplements patient blood with MSC-derived secretions during dialysis, addressing immune dysfunction in acute renal failure and promoting tissue repair.

Sentieon, Inc. is a biotechnology company founded in 2014 and headquartered in Mountain View, California, specializing in cloud-based bioinformatics solutions for the life sciences and clinical markets. The company develops a suite of bioinformatics tools designed for the efficient processing of genomics data, focusing on high accuracy and computational efficiency. Key products include Sentieon DNAseq, which facilitates germline DNA analysis, and Sentieon TNseq, used for detecting somatic variants in tumor-normal samples. Sentieon's software solutions are characterized by their scalability, deployability, and upgradability, allowing them to adapt to various user needs. The company's advanced algorithms and robust software implementation ensure rapid turnaround times and consistent results, benefiting scientists, clinicians, and patients by enhancing precision in genomic data analysis.

Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

Sialix Cancer Research provides cancer susceptibility antibodies and cancer-associated nucleoprotein antibodies for breast cancer. They also offer laser-based photodynamic endoscopic diagnosis using 5-aminolevulinic acid for early gastric adenocarcinoma and gastric adenoma.

Siamab Therapeutics is a biopharmaceutical company that focuses on developing therapies aimed at cancers characterized by the presence of abnormal carbohydrates, or glycans, on cancer cells. The company has created a technology platform that facilitates the discovery and development of anti-TACA therapeutic antibodies, which target tumor-associated carbohydrate antigens found in various solid tumors, including ovarian, prostate, pancreatic, gastric, and colon cancers. Founded in 2006 and based in Newton, Massachusetts, Siamab Therapeutics has licensed core technologies from the laboratory of glycobiology expert Ajit Varki. The company collaborates with a team of scientists and advisors specializing in oncology, glycoimmunology, and antibody engineering to advance its therapeutic programs.

Siamab Therapeutics is a biopharmaceutical company that focuses on developing therapies aimed at cancers characterized by the presence of abnormal carbohydrates, or glycans, on cancer cells. The company has created a technology platform that facilitates the discovery and development of anti-TACA therapeutic antibodies, which target tumor-associated carbohydrate antigens found in various solid tumors, including ovarian, prostate, pancreatic, gastric, and colon cancers. Founded in 2006 and based in Newton, Massachusetts, Siamab Therapeutics has licensed core technologies from the laboratory of glycobiology expert Ajit Varki. The company collaborates with a team of scientists and advisors specializing in oncology, glycoimmunology, and antibody engineering to advance its therapeutic programs.

Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.

Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.

Diffinity Genomics, Inc. is a biotechnology company based in West Henrietta, New York, that specializes in developing single-use disposable products for nucleic acid isolation and analysis in the life sciences sector. Founded in 2005, the company offers a range of products, including RapidTip, a functional pipette tip designed for purifying polymerase chain reaction (PCR) amplicons, and various other RapidTip variants that facilitate DNA purification for different applications, such as Sanger sequencing and downstream reactions. Diffinity Genomics serves a diverse clientele, including life science professionals engaged in DNA analysis, as well as industrial and academic research laboratories around the globe. The company utilizes proprietary technology to streamline nucleic acid purification processes, thereby enhancing efficiency in medical, industrial, and research settings.

Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.

LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.

MoMelan Technologies, Inc. is a company based in Cambridge, Massachusetts, specializing in the development of a device designed to treat skin disorders through the expansion of skin grafts. Founded in 2009, the company has created a tabletop device that can significantly increase the surface area of a small amount of harvested skin—up to approximately 100 times its original size. This innovative technology enables the grafting of expanded skin onto various areas affected by scars or other skin damage, thereby improving treatment options for patients. MoMelan operates as a subsidiary of Acelity L.P. Inc.

Bliss Health offers care management services through a network of integrated medical, nursing, and home care services.

Polytouch Medical specializes in developing advanced technologies for minimally invasive laparoscopic surgery, focusing primarily on hernia repair solutions. Their flagship product, PatchAssist, enhances mesh deployment and placement techniques, particularly for ventral hernias, allowing for quicker treatment initiation and improving the chances of successful outcomes for patients. The company collaborates closely with physicians to refine its offerings, ensuring that products are aligned with clinical needs. Supported by dedicated employees, medical advisors, and a knowledgeable board, Polytouch Medical aims to significantly enhance the quality of care in surgical practices and improve patient outcomes through innovative medical solutions.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, founded in 2008. The company specializes in developing portable point-of-care diagnostic platforms aimed at improving disease management worldwide, particularly in resource-poor settings. Its key offerings include the Daktari Virology platform for detecting Hepatitis C and HIV, the Daktari InSight data management service that facilitates connectivity between diagnostic systems and healthcare providers, and the Daktari Sickle Cell solution, which enables the identification of infants with sickle cell disease from a single drop of blood. Daktari's products are designed to provide real-time diagnostic information while ensuring that critical data flows efficiently throughout the healthcare system, ultimately supporting better clinical outcomes and global disease elimination efforts.